nlspharma.com - NLSP Net Assets per Single Share

Graphic logo of NLS Pharmaceutics (NLSP)

The net asset value per share for NLS Pharmaceutics AG (NLSP) reflects a value trend where the figure remains at 0.68. The issuer's revenues are based on the development of therapies for ADHD and narcolepsy. Management is strictly limiting expenses while awaiting confirmation of drug efficacy. Research into rare neurological pathologies in Europe and the US ensures the stability of this Swiss biotech.

NLS Pharma (NLSP): Share Book Value from 07/04/2022 to 10/31/2025

NLS Pharmaceutics Ltd. - analytical breakdowns and key metrics (NLSP)

- price and consensus price forecast:
Price Chart NLS Pharma|NLSP - Analyst Median Target
- market capitalization data:
Market Value NLS Pharmaceutics AG|NLSP - Full Business Value
- book capitalization data:
Net Assets per Single Share NLS Pharmaceutics|NLSP - Net Asset Value|Market Capitalization to Book Value Ratio nlspharma.com|NLSP - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital NLS Pharmaceutics AG|NLSP - Long-Term Debt to Capital|Short-Term Debt to Equity NLS Pharma|NLSP - Aggregate Debt Obligations|Debt to Book Capitalization Ratio NLS Pharmaceutics AG
Fundamental company valuation:nlspharma.com - NLSP
Manufactured products of NLS Pharma

The successful completion of clinical trials for sleep disorder therapies creates high potential asset value for NLS Pharmaceutics AG (NLSP). By analyzing the book value per share, an investor assesses the remaining equity after deducting all liabilities, which determines the real value of the ownership stake and confirms the fundamental stability of the quotes in the absence of hidden balance sheet degradation.

Competitors of NLS Pharmaceutics AG (NLSP)

Net Assets per Single Share JAZZ (Jazz Pharma)|CYTK: Net Assets per Share|Net Assets per Single Share PTC Therapeutics, Inc. (PTCT)|SRRK (scholarrock.com) - Share Book Value|Net Assets per Single Share Centessa CNTA|Share Book Value Dyne Therapeutics Inc|Edgewise Pharma (EWTX) - Book Value per Share|Accounting Value of a Share Rapport Corp (RAPP)|Book Value per Share ALMS (Alumis Inc.)|zevra.com - Book Value per Share|Net Assets per Single Share Contineum Therapeutics (CTNM)|LRMR: Accounting Value of a Share|CAPR (capricor.com) - Net Assets per Single Share|Entrada Therapeutics, Inc (TRDA) - Accounting Value per Share|PTHS (Channel Therapeutics) - Book Value per Share|Book Value per Share MediciNova Corp (MNOV)|Serina Therapeutics (SER) - Accounting Value per Share|Accounting Value of a Share BTAI (BioXcel Therapeutics Inc)|PMN - Net Assets per Single Share|Equity per Share Apimeds Pharmaceuticals, Inc. APUS|AEON (AEON Bio) - Book Value per Share|Bionomics Limited (BNOX) - Net Asset Value per Share|HUGE: Accounting Value per Share|RETA (Reata Pharmaceuticals Inc) - Book Value per Share